BRIEF-Biocartis Group strengthens biomarker portfolio for colorectal cancer

martes 26 de abril de 2016 01:11 GYT
 

April 26 (Reuters) - Biocartis Group NV :

* Announces the exclusive licensing of a recently detected set of mutations in the Epidermal Growth Factor Receptor (EGFR)that give resistance to anti-EGFR therapies in colorectal cancer Source text for Eikon: Further company coverage: (Gdynia Newsroom)